PDGFRA and myeloid neoplasm: The WHO diagnostic criteria for distinguishing KIT‐mutated SM from myeloid neoplasms with eosinophilia associated with the rearrangement of PDGFRα includes the haematological features of elevation of serum tryptase (usually > 20) and increased bone marrow mast cells38 with abnormal immunophenotype.